{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-068028","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2023-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.510487+00:00","generated_at":"2026-06-14T07:39:37.694498+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Structure Therapeutics dismisses PwC, engages EY as new auditor effective for FY2023","bullets":["Dismissed PwC as independent auditor on May 30, 2023; PwC's reports for 2021 and 2022 were unqualified.","Engaged EY as new independent auditor for fiscal year ending December 31, 2023, effective May 31, 2023.","No disagreements between Company and PwC on accounting principles, audit scope, or procedures.","Company disclosed prior material weaknesses in internal control over financial reporting (control environment, segregation of duties, ITGC).","PwC provided letter to SEC dated June 5, 2023, agreeing with Company's statements (filed as Exhibit 16.1)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-068028","json":"https://secwatch.observer/filing/0001104659-23-068028.json","markdown":"https://secwatch.observer/filing/0001104659-23-068028.md","text":"https://secwatch.observer/filing/0001104659-23-068028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923068028/0001104659-23-068028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923068028/tm2317694d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:39:37.694498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dffc48eb4f6ef21a2f00981e86ce24430a68bad5","claim":"Structure Therapeutics Inc. dismissed PricewaterhouseCoopers LLP as its auditor.","evidence_excerpt":"On May 30, 2023, the Audit Committee (the “Audit Committee”) of the Board of Directors of Structure Therapeutics Inc. (the “Company”) approved the dismissal of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923068028/0001104659-23-068028-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"PricewaterhouseCoopers LLP"}],"fact_type":"auditor_change"},{"claim_id":"f489effd1bcf4bdccf6182b4480d76b2bce304d0","claim":"Structure Therapeutics Inc. engaged Ernst & Young LLP as its auditor.","evidence_excerpt":"On May 30, 2023, the Audit Committee approved the engagement of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923068028/0001104659-23-068028-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Ernst & Young LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}